药物致急性肾损伤的法国药物警戒数据库病例-非病例研究
基于法国国家药物警戒数据库2015年自发报告的不良反应,采用病例-非病例设计分析药物致急性肾损伤(AKI)。抗菌药、利尿剂、肾素-血管紧张素系统药物、抗肿瘤药和抗炎药是最常涉及的药物类别。
要点
- 抗菌药(29.5%)、利尿剂(18.5%)和肾素-血管紧张素系统药物(16.3%)是AKI最常涉及的药物类别。
- 庆大霉素、依普利酮、螺内酯、坎地沙坦、顺铂和阿昔洛韦的报告比值比(ROR)最高(>10)。
- 66%的AKI病例涉及两种或以上同时使用的药物,15.2%的患者需要肾脏替代治疗。
核心结论
- 法国国家药物警戒数据库的病例-非病例研究可全面识别最常诱发AKI的药物类别,虽多数药物已知可致AKI,但应提高医生对触发这一潜在致死性状况的药物的认识。
研究设计与样本
- 研究为基于法国国家药物警戒数据库(FPVD)的病例-非病例研究,病例为2015年1月1日至2015年12月31日记录在FPVD的AKI报告,非病例为同期记录的其他自发报告不良反应(排除AKI),结果以报告比值比(ROR)及95%置信区间表示。
主要发现
- 共1254例患者发生AKI,男性占55%,平均年龄±标准差为68.7±15.0岁。
- 15.2%的患者需要肾脏替代治疗。
- 66%的AKI病例涉及两种或以上同时使用的药物。
- 最常涉及的药物类别为全身用抗菌药(29.5%)、利尿剂(18.5%)、肾素-血管紧张素系统药物(16.3%)、抗肿瘤药(10.2%)和抗炎药(5.4%)。
关键数值与推荐
- 庆大霉素、依普利酮、螺内酯、坎地沙坦、顺铂和阿昔洛韦的报告比值比(ROR)最高(>10)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Acute kidney injury (AKI) is associated with a high hospitalization rate, accelerated long-term decline in kidney function and a high mortality rate. Adverse drug reactions (ADRs) constitute one of the most important modifiable factors in the context of AKI. Most studies of drug-induced AKI have focused on a sole drug class. The objective of the present study was to establish a comprehensive overview of drug-induced AKI on the basis of spontaneously reported ADRs in the French national pharmacovigilance database (FPVD). METHODS: We performed a case-noncase study of drug-induced AKI. Cases corresponded to the reports of AKI recorded in the FPVD between 1 January 2015 and 31 December 2015. The noncases corresponded to all other spontaneously reported ADRs (excluding AKI) recorded in the FPVD during the same period. Data were expressed as the reporting odds ratio (ROR) and the 95% confidence interval. RESULTS: Of the 38 782 ADRs recorded in the FPVD during the study period, 3.2% were classified as cases of AKI. A total of 1254 patients experienced AKI (males: 55%; mean age ± standard deviation: 68.7 ± 15.0 years). Overall, 15.2% of the patients required renal replacement therapy. Two or more concomitantly administered drugs were involved in 66% of the cases of AKI. The most frequently implicated drug classes were antibacterial agents for systemic use (29.5%), diuretics (18.5%), agents acting on the renin-angiotensin system (16.3%), antineoplastic agents (10.2%) and anti-inflammatory agents (5.4%). Gentamicin, eplerenone, spironolactone, candesartan, cisplatin and acyclovir had the highest RORs (>10). CONCLUSION: A comprehensive study of a national pharmacovigilance database enabled us to identify the drug classes that most frequently induced AKI. Even though most of the identified drugs were already known to induce AKI, the present work should raise physicians' awareness of the compounds responsible for triggering this potentially life-threatening condition.
引用
- Pierson-Marchandise M, Gras V, Moragny J, et al. The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database. Br J Clin Pharmacol. 2017. PMID: 28002877. doi:10.1111/bcp.13216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。